Avinger - AVGR Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price objectives for Avinger's stock. Their AVGR share price forecasts range from $9.00 to $40.00. On average, they predict the company's stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 1,308.0% from the stock's current price.
View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts.

Avinger's stock was trading at $9.00 on January 1st, 2022. Since then, AVGR stock has decreased by 80.7% and is now trading at $1.74.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our AVGR earnings forecast.

Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings results on Thursday, November, 11th. The medical device company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.20. The medical device company earned $2.37 million during the quarter, compared to analyst estimates of $2.52 million. Avinger had a negative net margin of 219.16% and a negative trailing twelve-month return on equity of 183.34%. During the same period in the prior year, the business earned ($1.60) EPS.

Avinger's stock reverse split on the morning of Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), OrganiGram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).

(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Avinger's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (2.08%) and Renaissance Technologies LLC (0.51%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski and Mark Weinswig.
View institutional ownership trends.

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVGR stock can currently be purchased for approximately $1.74.

Avinger (NASDAQ:AVGR) has a market capitalization of $9.88 million and generates $10.13 million in revenue each year. The medical device company earns $-17,410,000.00 in net income (profit) each year or ($5.73) on an earnings per share basis.

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696.